We investigated the impact of MYC/BCL-2 protein co-expression on the prognosis of diffuse large B-cell lymphoma(DLBCL)patients and observed whether double expression(DE)remains an independent poor prognostic factor in DLBCL after the addition of therapeutic factors such as DA-EPOCH-R, central prophylaxis, and transplantation. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.